Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

IPSC

+ Watchlist+ Portfolio

Century Therapeutics, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.37
52-Week Range
$0.46 – $3.04
Market Cap
$250.60M
P/E (TTM)
—
EPS (TTM)
-0.64
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.19
PEG Ratio
—
Return on Equity
-51.16%
Return on Assets
-25.52%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
8.74
Debt/Equity
0.18
Total Debt
$37.49M
Free Cash Flow
$-57.54M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$170.89M

Market Snapshot

About

Century Therapeutics is a biotechnology company developing innovative cell therapies for cancer treatment. The company engineers induced pluripotent stem cells (iPSCs) to create allogeneic CAR-T and CAR-NK cell therapies that can be manufactured at scale. Century's platform aims to overcome limitations of autologous cell therapies by providing off-the-shelf treatments with improved persistence and functionality. The company is advancing multiple programs through clinical development targeting hematologic malignancies and solid tumors.